Observational cohort of patients with worsening idiopathic pulmonary fibrosis
Pulmonary Fibrosis Biomarkers During Exacerbation
This study is tracking patients with worsening idiopathic pulmonary fibrosis who need to be hospitalized to see how different biological markers relate to their health and quality of life over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Gentofte, Copenhagen Academic / other |
| Locations | 1 site (Hellerup, Copenhagen) |
| Trial ID | NCT04442711 on ClinicalTrials.gov |
What this trial studies
This study follows patients with idiopathic pulmonary fibrosis (IPF) who experience exacerbations requiring hospitalization. It aims to collect clinical and biological data to assess the diagnostic and prognostic value of various biomarkers during these exacerbations. Patients are recruited within 24 hours of hospital admission, and their clinical outcomes and quality of life are also evaluated over a longitudinal follow-up period of up to five years. The study builds on the existing PFBIO cohort to enhance understanding of IPF exacerbations.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with IPF and are experiencing an exacerbation requiring hospitalization.
Not a fit: Patients who are unable to provide informed consent or those not experiencing an exacerbation of respiratory symptoms will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients experiencing exacerbations of IPF.
How similar studies have performed: While this study builds on existing cohorts, the specific focus on exacerbations in IPF patients is a relatively novel approach that has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Admitted with an increase in respiratory symptoms * Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA * Age at least 18 years Exclusion Criteria: * Unable to provide informed consent
Where this trial is running
Hellerup, Copenhagen
- Herlev and Gentofte Hospital — Hellerup, Copenhagen, Denmark (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.